All In Biotech

Drug Trial Radar · NCT06858332

Lipoprotein(a) Levels in Patients With Atherosclerotic Cardiovascular Diseases in Russia

Last checked: Nov 19, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

2,382

Planned (sponsor's estimate)

Start

Apr 15, 2025

Primary completion

Sep 30, 2027

Study completion Sep 30, 2027

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Mar 5, 2025

More drug trials from this sponsor

Design

Study type
Observational
Who can join
All sexes, from 18 years, up to 99 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study has the purpose to answer how the Lipoprotein(a) (Lp(a)) level is distributed among Atherosclerotic cardiovascular disease (ASCVD) patients in Russia, and what is the connection between elevated levels of this parameter and the cardiovascular disease (CVD) risk.

Conditions

  • Atherosclerotic Cardiovascular Disease

Interventions

  • AtorvastatinDrug

    3-Hydroxy-3-methylglutaryl-CoA reductase inhibitors (statins)

  • SimvastatinDrug

    3-Hydroxy-3-methylglutaryl-CoA reductase inhibitors (statins)

  • RozuvastatinDrug

    3-Hydroxy-3-methylglutaryl-CoA reductase inhibitors (statins)

  • EzetimibeDrug

    Ezetimibe

  • NiacinDrug

    Niacin

  • CiprofibrateDrug

    Fibrates

  • FenofibrateDrug

    Fibrates

  • BezafibrateDrug

    Fibrates

  • EvolocumabDrug

    PCSK9 inhibitor

  • AlirocumabDrug

    PCSK9 inhibitor

  • InclisiranDrug

    Small interfering RNA

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of patients (%) with Lp(a) ≥125 nmol/LTime frame: Baseline
  2. The difference in the number of patients with cardiovascular events (%) between the groupsTime frame: 24 months

Locations

20 sites in 1 country. Site status is shown where the registry gives one.

  • Novartis Investigative Site

    Chelyabinsk, Russia · Recruiting

  • Novartis Investigative Site

    Chelyabinsk, Russia · Recruiting

  • Novartis Investigative Site

    Kaluga, Russia · Recruiting

  • Novartis Investigative Site

    Kemerovo, Russia · Recruiting

  • Novartis Investigative Site

    Krasnoyarsk, Russia · Recruiting

  • Novartis Investigative Site

    Moscow, Russia · Recruiting

  • Novartis Investigative Site

    Moscow, Russia · Recruiting

  • Novartis Investigative Site

    Moscow, Russia · Recruiting

  • Novartis Investigative Site

    Omsk, Russia · Recruiting

  • Novartis Investigative Site

    Perm, Russia · Recruiting

  • Novartis Investigative Site

    Ryazan, Russia · Recruiting

  • Novartis Investigative Site

    Surgut, Russia · Recruiting

  • Novartis Investigative Site

    Tomsk, Russia · Recruiting

  • Novartis Investigative Site

    Tyumen, Russia · Recruiting

  • Novartis Investigative Site

    Vladimir, Russia · Recruiting

  • Novartis Investigative Site

    Vladivostok, Russia · Recruiting

  • Novartis Investigative Site

    Voronezh, Russia · Recruiting

  • Novartis Investigative Site

    Yakutsk, Russia · Recruiting

  • Novartis Investigative Site

    Yekaterinburg, Russia · Recruiting

  • Novartis Investigative Site

    Yekaterinburg, Russia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.